Surgical Management of Sarcoma Metastatic to Liver

Brett L Ecker; Robert G Maki; Michael J Cavnar; Ronald P DeMatteo

doi:10.1016/j.soc.2020.08.002

Surgical Management of Sarcoma Metastatic to Liver

Surg Oncol Clin N Am. 2021 Jan;30(1):57-67. doi: 10.1016/j.soc.2020.08.002. Epub 2020 Oct 20.

Authors

Brett L Ecker¹, Robert G Maki², Michael J Cavnar³, Ronald P DeMatteo⁴

Affiliations

¹ Department of Surgery, University of Pennsylvania, 3400 Spruce st, Philadelphia, PA 19104, USA. Electronic address: Brett.Ecker@uphs.upenn.edu.
² Department of Medicine, University of Pennsylvania, 3400 Spruce st, Philadelphia, PA 19104, USA.
³ Department of Surgery, University of Kentucky, 800 Rose St First Floor, Lexington, KY 40536, USA.
⁴ Department of Surgery, University of Pennsylvania, 3400 Spruce st, Philadelphia, PA 19104, USA.

PMID: 33220809
DOI: 10.1016/j.soc.2020.08.002

Abstract

Sarcomas are rare mesenchymal tumors with a propensity for hematogenous metastasis. Gastrointestinal stromal tumor (GIST) is the most common histologic subtype and the most common source of hepatic metastases. In the case of metastatic GIST, neoadjuvant imatinib can be used as a selection tool for the judicious application of surgery, where treatment-responsive patients who undergo resection to prevent the development of treatment-resistant clones have associated 10-year actuarial survival of 40%. Further advances for many of the non-GIST sarcoma subtypes will depend on the development of improved systemic therapies and evaluation of their activity in subtype or molecularly defined trials.

Keywords: GIST; Gastrointestinal stromal tumor; Hepatic tumor; Imatinib; Metastasis; Sarcoma.

Publication types

Review

MeSH terms

Antineoplastic Agents* / therapeutic use
Gastrointestinal Neoplasms* / drug therapy
Gastrointestinal Stromal Tumors* / drug therapy
Gastrointestinal Stromal Tumors* / surgery
Humans
Liver
Sarcoma* / drug therapy
Sarcoma* / surgery

Substances

Antineoplastic Agents